CCG Wealth Management’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.16M Sell
4,612
-180
-4% -$38.7K 0.27% 54
2026
Q1
$1.04M Buy
4,792
+2,398
+100% +$532K 0.28% 54
2025
Q4
$547K Buy
2,394
+492
+26% +$112K 0.23% 57
2025
Q3
$440K Buy
1,902
+92
+5% +$18.7K 0.21% 49
2025
Q2
$336K Sell
1,810
-46
-2% -$8.55K 0.18% 58
2025
Q1
$389K Buy
1,856
+127
+7% +$24.7K 0.23% 53
2024
Q4
$307K Buy
1,729
+35
+2% +$6.43K 0.17% 56
2024
Q3
$335K Buy
1,694
+84
+5% +$15.7K 0.19% 54
2024
Q2
$276K Buy
1,610
+160
+11% +$26.5K 0.16% 54
2024
Q1
$264K Buy
+1,450
New +$250K 0.16% 58
2023
Q4
Sell
-1,595
Closed -$238K 55
2023
Q3
$238K Buy
+1,595
New +$234K 0.16% 52
2023
Q2
Sell
-1,482
Closed -$236K 66
2023
Q1
$236K Sell
1,482
-41
-3% -$6.27K 0.16% 55
2022
Q4
$246K Sell
1,523
-31
-2% -$4.75K 0.14% 82
2022
Q3
$209K Buy
1,554
+37
+2% +$5.31K 0.13% 88
2022
Q2
$232K Buy
+1,517
New +$232K 0.13% 90
2020
Q1
Sell
-2,528
Closed -$224K 63
2019
Q4
$224K Sell
2,528
-302
-11% -$25.1K 0.14% 87
2019
Q3
$214K Buy
+2,830
New +$194K 0.15% 74

Other funds holding ABBV

CCG Wealth Management's ABBV Position: Q2 2026 in Review

CCG Wealth Management reduced its AbbVie (ABBV) stake by 3.8% in Q2 2026, selling an estimated $38.7K and leaving 4,612 shares worth $1.16M. The position accounts for 0.27% of the portfolio, ranked #54.

CCG Wealth Management first reported a position in ABBV in Q3 2019 and has held it in 17 quarters since. 4,201 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • CCG Wealth Management held 4,612 shares of AbbVie worth $1.16M as of Q2 2026.
  • CCG Wealth Management sold 180 AbbVie shares in Q2 2026, an estimated $38.7K.
  • AbbVie made up 0.27% of CCG Wealth Management's portfolio in Q2 2026, its #54 holding.
  • CCG Wealth Management first reported a position in AbbVie in Q3 2019 and has held it in 17 quarters since.
  • 4,201 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on CCG Wealth Management's 13F filing for Q2 2026, filed 7 Aug 2026.